David Heigener introduces a new pathway tool for Europe designed to help clinicians

(1:1econd)

ASCO 2017 - David Heigener Interview Part 1

(1:42)

David Heigener reports from the IASLC 20th WCLC symposium

(2:)

ASCO 2017 - David Heigener Interview Part 2

(1:37)

David Heigener reports from the IASLC 20th WCLC symposium

(1:50)

David Heigener presents for a symposium at IASLC 20th WCLC 2019

(58)

Tests génétiques avant le mariage - Rav Benjamin DAVID - Institut Pouah

(7:34)

ONE DAY AT THE HARVARD UNIVERSITY

(26:41)

Treatments AGAINST Tumor Angiogenesis

(4:27)

Scientist Stories: David Balding, How the causes of complex disease are distributed in the genome

(30:10)

Harvard University Campus Tour

(9:50)

Scientist Stories: Dave Schaffer, Pioneer in Bioengineering and Gene Therapies

(54:18)

Panel Presentation: Understanding iRAEs from Immune Checkpoint Inhibitors

(5:24)

Optimale Behandlung geht nur im Team

(3:44)

Dr David Levy Pix11

(4:7)

ASCO lung cancer highlights

(1:30)

WCLC 2019: David Heigener discussing clinical trials in second-line treatment

(2:11)

WCLC 2019: David Heigener discussing anti-angiogenic vs immune checkpoint inhibitor

(1:1econd)

WCLC 2019: David Heigener discussing clinical trials in second-line treatment (2)

(2:12)

WCLC 2019: David Heigener discussing 'My personal approach to second-line treatment in 2019'

(1:55)

WCLC 2019: David Heigener discussing future perspectives in second-line NSCLC treatment

(2:)

Kidney Organiods: Flow-Enhanced Vascularization and Maturation In Vitro

(1:59)

TGen's COVID-19 Update Episode 4

(2:31)

Checkpoint Inhibitors in Second and Third-line

(4:19)

COVID-19 Webinar [Clip]: Why We Can't Rely on Antibody Testing to Reboot the U.S. Economy

(28)

Upfront Immunotherapy for PD-L1+ NSCLC

(8:44)

Combined Immunotherapy and Chemotherapy for NSCLC

(5:27)

2050: Bioethical Issues | 17/27 S5 Opening - David Heyd

(6:39)

Antiangiogenic Therapy in NSCLC: Addressing the Unknown

(5:48)

2016 Immune Engineering Hidde Ploegh

(26:35)